Kuvan (Sapropterin Dihydrochloride)

Sapropterin dihydrochloride provides the synthetic form of the natural cofactor tetrahydrobiopterin (BH4). By increasing the availability of BH4, it stabilises and activates phenylalanine hydroxylase, the enzyme that converts phenylalanine to tyrosine, thereby enhancing phenylalanine clearance from the bloodstream.

The dose of Kuvan is individualized. A prescribing clinician determines the appropriate amount based on the patient’s BH4‑responsiveness, baseline blood phenylalanine concentration, age, weight, and dietary intake. Dose adjustments are made according to regular monitoring of phenylalanine levels.

Safety data for Kuvan in pregnancy and lactation are limited. The decision to use the medication during pregnancy or while breastfeeding should be based on a careful risk‑benefit assessment by the treating physician, considering the potential impact of uncontrolled phenylalanine levels on the fetus or infant.

To order Kuvan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to Kuvan is strict dietary restriction of phenylalanine without pharmacologic BH4 supplementation. Kuvan offers a pharmacologic option that can reduce phenylalanine levels and permit a less restrictive diet in BH4‑responsive patients, whereas diet‑only management relies solely on limiting phenylalanine intake.

Kuvan tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight and excessive heat. Keep the container tightly closed and out of reach of children.

Kuvan is taken orally as a tablet. It may be swallowed with water, with or without food, as directed by the prescribing clinician. Patients should follow the dosing schedule provided by their healthcare professional and maintain regular monitoring of blood phenylalanine levels.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, thrombocytopenia (low platelet count), and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, difficulty breathing, unusual bruising, or jaundice.

Kuvan should not be used by individuals with known hypersensitivity to sapropterin dihydrochloride or any tablet excipients, and it is not indicated for patients with PKU who are non‑responsive to BH4 therapy. Clinicians should also exercise caution in patients with severe renal impairment until safety is established.